Carmat is up more than 10% on the back of favorable comments from EuroLand Corporate, which initiates coverage on the stock at 'buy' with a price target of 6.8 euros, highlighting the company's ability to 'revolutionize the heart failure market'.

Given the company's progress, the lack of alternatives in the field of total artificial hearts, and the sector's colossal needs, we feel that the company is clearly undervalued, with an upside of +215%", believes the analyst.

Copyright (c) 2024 CercleFinance.com. All rights reserved.